A Phase II Study of Cetuximab Plus Irinotecan in Patients With EGFR-detectable Metastatic Colorectal Carcinoma

• Status: Completed
• Trial end date: 2006-07-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the response rate of cetuximab plus irinotecan combination therapy in subjects with EGFR-detectable metastatic colorectal carcinoma who have documented progressive disease to irinotecan-based chemotherapy and who have failed (progressive disease or intolerance) previous oxaliplatin-based and fluoropyrimidine-based chemotherapies.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Cetuximab; Irinotecan

Criteria

Inclusion Criteria:

• The subject must have surgically unresectable metastatic colorectal carcinoma.

• The subjects who have received and failed Ilinotecan, oxaliplatin and fluoropyrimidine-based chemotherapy

• ECOG PS 0-2

Exclusion Criteria:

• Subjects with symptomatic cerebral metastasis